Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALYM
2024-516181-11-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of valemetostat in mature B-cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL) and 3 more, sponsored by LYSARC. Primary endpoint: overall response rate. Planned start Sep 2024; status: authorised.
02
Drugs
valemetostat
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on 2024-516181-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516181-11-00.